East Grinstead

Researchers are investigating the safety and effectiveness of the ELIOS device compared to a competitor device in patients with open-angle glaucoma undergoing cataract surgery. The study focuses on adults aged 40 years and older who have mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma and a visually significant cataract suitable for phacoemulsification. The main goal is to see how well these treatments lower intraocular pressure (IOP) 12 months after surgery. Participants will undergo cataract surgery followed by treatment with either the ELIOS device or a competitor device as determined by the surgeon. Both treatments are delivered as procedures immediately after the cataract surgery. The study is designed as a prospective, multicenter, randomized clinical trial to compare these two approaches. During the study, participants will be monitored for effectiveness by measuring intraocular pressure at 12 months post-operation. Safety and other outcomes will also be evaluated throughout the study period. Participation involves follow-up visits and assessments to track eye pressure and overall eye health after treatment, ensuring thorough monitoring of results over time.

Researchers are evaluating the safety and outcomes of different surgical margin sizes for adults with stage II primary invasive cutaneous melanoma. The trial compares the effects of removing 1 cm versus 2 cm of healthy skin around the melanoma site to see if smaller margins provide similar disease control. This study aims to understand if narrower excision margins can reduce surgery side effects and improve quality of life without increasing the risk of melanoma returning. Participants will be randomly assigned to undergo wide local excision surgery with either a 1 cm or 2 cm margin around the original melanoma scar. Both approaches involve removing an extra margin of skin to eliminate any remaining melanoma cells after the initial biopsy. Surgery is scheduled to be completed within 120 days after diagnosis and within 28 days after randomization. This phase III, multi-center trial will assess if the smaller margin is as effective as the larger one. During the study, patients will be followed for up to 60 months to monitor disease-free survival, which means the length of time without melanoma recurrence. Researchers will also evaluate quality of life, side effects from surgery, and the economic impact on health services. Participants will have regular clinical assessments, and outcomes will be recorded to determine the long-term safety and benefits of the two surgical approaches.

Glaucoma is a leading cause of vision loss and blindness worldwide, particularly affecting people over 50 years old. Open-angle glaucoma (OAG) is the most common form, caused by increased pressure in the eye damaging the optic nerve over time. This trial studies whether adding oral nicotinamide (a form of Vitamin B3) to standard eye pressure-lowering treatments can reduce vision loss in adults recently diagnosed with OAG. The research also aims to assess the long-term safety and effectiveness of nicotinamide in protecting vision by improving mitochondrial function, which is essential for nerve cell health. Participants will be randomly assigned to receive either nicotinamide tablets or a matching placebo, in addition to their usual glaucoma care such as eye drops or laser therapy. This phase III trial is double-masked, meaning neither the participants nor the investigators know which treatment is given to ensure unbiased results. The study focuses on adults with early to moderate OAG and normal eye angle, and treatment will continue while monitoring vision changes over time. Throughout the study, participants will undergo regular eye examinations including visual field tests to measure changes in vision, with the main outcome measured at 27 months. Researchers will monitor safety through clinical evaluations and laboratory tests, ensuring participants adhere to the treatment and attend scheduled visits. The trial seeks to determine if nicotinamide can safely slow the progression of vision loss in glaucoma patients over more than two years of follow-up.